The 2022 Endpoints 11 is coming. Do you know a biotech that should be on the list? - Endpoints News

It’s time for some fun. Over the past 20 years or so, I’ve made it my mission to hunt down some of the most promising private biotechs in the industry to feature in an annual report I now call the Endpoints 11. And we’re back on track for the next

Having already secured several approvals for Duchenne muscular dystrophy drugs, Sarepta aimed to capitalize on its lead in the field with a new data readout Wednesday. And while many of the hard numb… [+672 chars]

full article...